Xilio Therapeutics, Inc. (XLO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Xilio Therapeutics, Inc. (XLO) Bundle
Looking to determine the intrinsic value of Xilio Therapeutics, Inc.? Our XLO DCF Calculator integrates real-world data with comprehensive customization features, allowing you to adjust forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -17.1 | -53.5 | -73.7 | -85.6 | -73.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .2 | 1.1 | 1.5 | 1.8 | 1.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -17.3 | -54.6 | -75.2 | -87.4 | -75.7 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 48.8 | 19.2 | 198.1 | 120.4 | 44.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.5 | 5.4 | 3.1 | 3.1 | 1.1 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.7 | -2.2 | -1.1 | -1.9 | -.5 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -17.3 | -54.6 | -73.7 | -86.5 | -75.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.3 | -52.8 | -75.6 | -86.5 | -76.4 | -1.1 | .0 | .0 | .0 | .0 |
| WACC, % | 5.11 | 5.11 | 5.08 | 5.1 | 5.11 | 5.1 | 5.1 | 5.1 | 5.1 | 5.1 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -33 | |||||||||
| Equity Value | 32 | |||||||||
| Diluted Shares Outstanding, MM | 27 | |||||||||
| Equity Value Per Share | 1.17 |
What You Will Get
- Real XLO Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Xilio Therapeutics' future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Xilio Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Watch Xilio Therapeutics’ intrinsic value update instantly.
- Intuitive Visual Outputs: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing Xilio Therapeutics, Inc.'s (XLO) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth projections, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for Xilio Therapeutics, Inc. (XLO)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Variables: Easily adjust inputs to suit your financial modeling needs.
- Real-Time Feedback: Monitor immediate changes to Xilio’s valuation as you modify data points.
- Pre-Configured Data: Comes with Xilio’s latest financial metrics for swift assessments.
- Relied Upon by Experts: Utilized by financial analysts and investors for strategic decision-making.
Who Should Use This Product?
- Investors: Accurately assess Xilio Therapeutics, Inc.'s (XLO) fair value to inform investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Acquire knowledge of financial modeling techniques employed by leading biotech firms.
- Educators: Implement it as a resource for teaching valuation practices in finance courses.
What the Template Contains
- Historical Data: Includes Xilio Therapeutics, Inc.'s (XLO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Xilio Therapeutics, Inc.'s (XLO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Xilio Therapeutics, Inc.'s (XLO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.